BioVaxys Technology Corp. Closes $537,500 Funding Round

The company finalizes third tranche and prepares for fourth tranche of private placement.

VANCOUVER, BC, Jan. 10, 2025 /CNW/ — BioVaxys Technology Corp. BIOV 5LB announced today the completion of its third tranche (the “Third Tranche“) of a previously revealed non-brokered private placement (the “Private Placement“). The company issued 10,750,000 units (the “Units“) at a price of $0.05 per Unit, generating gross proceeds of $537,500.

Each Unit comprises one common share (a “Share“) and one purchase warrant (a “Warrant“). Each Warrant allows the holder to purchase an additional Share at an exercise price of $0.15 until January 10, 2027, two years from the issuance date.

BioVaxys plans to use the net proceeds from the Third Tranche for general working capital. The company did not pay any finder’s fees in connection with this tranche. All securities issued are subject to a statutory hold period, which ends on May 11, 2025, four months and one day after issuance, in accordance with applicable securities regulations.

The company expects to close the fourth and final tranche of the Private Placement by January 24, 2025.

Additionally, following its news release on December 13, 2024, BioVaxys reports it has issued 5,000,000 unrestricted Shares at a deemed price of $0.10 per Share. This equates to a total of $500,000 in debt settled with an arm’s-length consultant (the “Debt Settlement“).

This news release does not represent an offer to sell or a solicitation for any securities within the United States. The securities mentioned have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States without complying with registration requirements or available exemptions.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), registered in British Columbia, Canada, focuses on novel immunotherapies designed to enhance patient outcomes using its DPX™ immune-educating technology and HapTenix© ‘neoantigen’ tumor cell construct for tackling cancers, infectious diseases, and other immunological conditions. The patented DPX™ platform enables targeted and durable immune responses while showing promise in both pre-clinical and clinical studies. BioVaxys trades on the Canadian Securities Exchange under the ticker “BIOV”, on the Frankfurt Bourse 5LB, and is quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on social media platforms X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin” 
James Passin, Chief Executive Officer
Phone: +1 740 358 0555

Cautionary Statements Regarding Forward Looking Information

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements“) under applicable securities legislation. These include statements related to the Private Placement, including anticipated use of proceeds and details regarding the final tranche. Forward-looking statements often contain words such as “expects,” “anticipates,” and “intends,” or similar phrases, suggesting expectations regarding future events.